CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma
Personalized drug combos extend life in brain cancer
This phase I trial tested a genomically tailored multiagent regimen in 30 adults with recurrent glioblastoma. Median overall survival was 12…
A new approach using tailored drug combinations is helping some patients with recurring brain cancer live longer, offering fresh hope where …
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
Imlunestrant shows OS benefit in ESR1-mutated advanced breast cancer in Phase III trial
A New Pill Combo Helps Women with Advanced Breast Cancer Live Longer
A Phase III RCT of 874 endocrine-pretreated ER+/HER2- advanced breast cancer patients found imlunestrant monotherapy improved median OS vers…
A new pill combo helps women with advanced breast cancer live longer and delays the need for harsh chemotherapy.